MorphoSys (ETR:MOR) Trading 0.4% Higher

MorphoSys AG (ETR:MOR)’s share price rose 0.4% during mid-day trading on Thursday . The stock traded as high as €67.85 ($72.96) and last traded at €67.85 ($72.96). Approximately 7,361 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 153,687 shares. The stock had previously closed at €67.60 ($72.69).

MorphoSys Stock Performance

The business’s 50 day moving average is €67.55 and its 200 day moving average is €58.96. The stock has a market capitalization of $2.56 billion, a PE ratio of -12.27, a PEG ratio of 0.06 and a beta of 0.60. The company has a current ratio of 1.38, a quick ratio of 3.49 and a debt-to-equity ratio of 3,454.18.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.